Methicillin-resistant S. aureus (MRSA) has emerged as the most common hospital-acquired pathogen and is associated with increased morbidity and mortality compared with other strains. Vancomycin has been the cornerstone of treatment of patients with serious MRSA infections for some decades and while more than 99% of clinical S. aureus isolates remain susceptible to vancomycin, we are beginning to see strains of MRSA with reduced susceptibility. This review discusses this phenomenon, the predictors of infection with such forms of MRSA, and current and future management options.
Introduction
Methicillin-resistant S. aureus (MRSA) has emerged as the most common hospital acquired pathogen, accounting for >60% of the clinical S. aureus isolates recovered in US intensive care units [1] . Infection with MRSA is associated with increased morbidity, requirement of longer duration of antibiotic therapy, higher healthcare costs, prolonged hospitalization and an increased risk of death [2, 3] . This risk is more pronounced in patients who have been treated sub-optimally, either with an ineffective antibiotic and/or inadequate surgical intervention.
Vancomycin has been the cornerstone of treatment of patients with serious MRSA infections. Consequently, vancomycin use has been increasing since the mid-1980's, resulting in the emergence of MRSA with reduced susceptibility to vancomycin. In patients with S. aureus bacteremia, higher vancomycin minimum inhibitory concentrations (MICs) have been associated with prolonged bacteremia or increased mortality [4] . While vancomycin non-susceptible strains (see Table 1 ), in the form of intermediate-resistant S. aureus, (VISA, vancomycin MIC 4-8 mg/L) remain rare and vanA-mediated vancomycin-resistant S. aureus (VRSA, vancomycin MIC > 16 mg/L) are limited to a handful of reported cases, the rising MICs of vancomycin among vancomycin susceptible S. aureus, referred to as the 'vancomycin MIC creep', has caused a re-evaluation of vancomycin susceptibility criteria in cases of complicated infections like bacteremia and/or pneumonia [4, 5] . This report will discuss the phenomenon of vancomycin MIC creep in S. aureus, its potential association with decreased vancomycin efficacy, the predictors of infections with MRSA with high vancomycin MIC, and briefly review the current and future management options.
Vancomycin -the early years
Vancomycin is a complex tricyclic glycopeptide that was first isolated from Amycolatopsis orientalis found in a soil sample from Borneo in the mid 1950s that has activity against most clinically relevant Gram-positive pathogens [6] . In 1958, vancomycin was introduced for clinical use against penicillin-resistant S. aureus, but for the first 25 years after introduction, its use remained limited to patients with severe beta-lactam allergy and with MRSA infection, which were infrequent prior to 1980. However, the 1980s were marked by a surge in the use of cephalosporin and quinolone antibiotics in hospitals, which paralleled the emergence of methicillin resistance initially in coagulase-negative staphylococci and subsequently S. aureus. During this early period, vancomycin dosing was centered around avoidance of nephrotoxicity and dosing convenience rather than efficacy or prevention of developing resistance, with target serum trough concentrations of 5-10 mg/L. In contrast, recent consensus guidelines have recommended troughs of 15-20 mg/L in the treatment of serious MRSA infections, not only for increasing pharmacodynamic exposure to improve in vivo efficacy but also to prevent selection of S. aureus strains with higher MICs that have been demonstrated in vitro in vancomycin concentrations < 10 mg/L [7] . It is important to realize that a robust risk-benefit analysis for pushing serum concentrations of vancomycin to these heights is so far lacking.
Vancomycin susceptibility testing
For antimicrobials, various laboratory methods of susceptibility testing against strains of bacteria are used to predict clinical response. The simplest of these assays is the "MIC", which refers to the lowest concentration of antibiotic that inhibits visible growth of a standard inoculum size of bacteria (generally 10 4 cfu for staphylococci) after overnight incubation in Mueller-Hinton broth. A result of "susceptible" by a clinical microbiology laboratory is considered to be predictive of a satisfactory clinical response whereas "nonsusceptible" or "resistant" predicts failure. While beyond the scope of this article, readers must appreciate that establishing these MIC socalled "breakpoints" for strains that are susceptible, intermediate, and resistant to antibiotics is controversial and wrought with laboratory oversimplifications of a very complex host-pathogen-antibiotic relationship. In short, microbiological breakpoints (maximum MIC thresholds for predicting successful treatment) are established by combining data of MIC distributions of groups of clinical strains and available pharmacodynamic and pharmacokinetic information, but not on any data that correlates clinical response to MIC. Furthermore, the MIC measures inhibition of growth, not killing potency of an antibiotic. Such methods are much more time consuming and are rarely used and/or available to clinicians in a timely manner. Finally, in vitro assays of susceptibility like MIC measurements completely ignore any potential interaction of the antibiotic with innate host defense mechanisms that may occur in vivo.
Various tests and methodologies with variable sensitivity and specificity are available to measure vancomycin MICs. Broth microdilution is considered to be the gold standard for measuring vancomycin MIC. However, broth microdilution can be a cumbersome test and is not used routinely in clinical laboratories. Since it is reliant on a two-fold dilution, it offers limited quantitative information. Also, agar disc diffusion is not a suitable test for large molecules like vancomycin and moreover it does not measure the MIC directly and cannot detect VISA isolates. Currently, most clinical laboratories use Etest and automated susceptibility tests for measuring the vancomycin MIC. However, automated testing has been associated with underestimation of vancomycin MIC when compared to Etest and broth microdilution [8] . In 2006, CLSI revised the susceptibility breakpoints for vancomycin in response to evidence that vancomycin was poorly effective against MRSA isolates with MIC > 4 mg/L [4].
Vancomycin resistance and heteroresistance VRSA VRSA (vancomycin resistant S. aureus) isolates remain rare and sporadic. Since the first report in 2002, there have been 13 confirmed cases of VRSA [9] from US, and one each from India and Iran). A few existing factors that seem to predispose patients to VRSA infection include prior MRSA and vancomycin-resistant enterococcal infections or colonization, underlying chronic medical conditions, and previous extensive treatment with vancomycin [10] .
VISA and hVISA S. aureus isolates with broth microdilution MIC 4-8 μg/mL are termed as VISA. This definition has been excluded from the new EUCAST breakpoints which define an isolate with broth microdilution MIC ≥ 4μg/mL as resistant rather than (Figure 1 ). Quantitative definitions used for hVISA are an AUC (area under the curve) ratio of ≥ 0.9 of the AUC of type strain Mu3 (PAP/AUC) or modified highinoculum Etest read at 48 h [11, 9] .
The hVISA phenotype is considered to be a precursor to VISA, and falls on the same continuum on the heteroresistance spectrum. The first case of hVISA was reported in Japan in 1996. Current reported prevalence of hVISA is variable (0-74%) because of difficulty of detection, cumbersome and non-standardized detection methods, variable selective vancomycin pressure, and instability of the phenotype once some isolates are frozen and stored [9] . The main risk factors for infections caused by VISA and hVISA strains are prior MRSA infection with high bacterial load (endocarditis, deep abscess, prosthetic joint infections) and prior vancomycin exposure (particularly a low serum concentration). Nosocomial spread and rare outbreaks caused by hVISA or VISA strains have also been reported.
The above discussion points out an obvious inherent flaw in establishing a microbiological breakpoint for vancomycin that correlates cleanly with clinical response. Vancomycin heteroresistance in hVISA is characterized by the existence of subpopulations of organisms among vancomycin-susceptible strains that are able to grow in concentrations of vancomycin in the range of intermediate-resistant organisms. This property is present in all staphylococci but in varying degrees. If the proportion of organisms in the bacterial population is sufficiently high to be detected with standard low inocula of susceptibility testing, they may be detected and appropriately considered nonsusceptible. However, if the proportion of organisms in a bacterial population that can grow in vancomycin >2 mg/L is below the frequency of the testing inoculum density, then the strain will be characterized as susceptible by standard susceptibility testing. Infections with high bacterial load (e.g. pneumonia, endocarditis, abscess) will not only have a high risk for vancomycin treatment failure but also risk the rapid development of vancomycin intermediate resistance (VISA), especially if vancomycin is under-dosed and the organisms are exposed to vancomycin concentrations <10g/L [12] . This latter process is simply "enriching" the already present bacterial population for vancomycin-resistant subspecies to the point where subsequent susceptibility testing, after selection, will appropriately characterize these strains as VISA.
It is important to also consider that in situations where the infection is characterized by low bacterial inocula (e.g. UTI, simple cellulitis without abscess), vancomycin heteroresistance, and, therefore, the MIC creep, is likely to be less clinically relevant, if at all. The higher the vancomycin MIC, the more likely that a strain will exhibit subpopulations that can be grown in ranges of vancomycin concentrations comparable to vancomycin non-susceptible strains ( Figure 2 ). Therefore, a highinoculum infection like endocarditis caused by a vancomycin-susceptible S. aureus with an MIC of 2 mg/L is much more likely to fail vancomycin therapy than a low-inoculum infection such as a surgical wound infection without an abscess where the vancomycin MIC is lower. Both strains are vancomycin "susceptible", but clinical susceptibility to the drug is different in each of these cases.
Vancomycin Pharmacodynamics
Based on neutropenic mouse models, in vitro studies and limited data from human studies, the AUC/MIC ratio has been used as a preferred parameter for measuring the effectiveness of vancomycin in treating S. aureus infections [13, 14] . A specific AUC/MIC threshold of 400 has been advocated as a target to achieve clinical effectiveness with vancomycin, based on the initial clinical data from pneumonia [15] and more recent data from bacteremia [16] . These considerations superimposed on the vancomycin MIC creep have provided circumstantial evidence, without clinical trial validation, to support higher vancomycin trough concentrations in the 15-20 mg/L range. Using Monte Carlo simulations, it has been suggested that the probability of attaining this ratio is approximately 100% only in isolates with MIC≤0.5 mg/L and the probability falls to 0% in isolates with MIC of 2mg/L [17] . Based on simulated models, it has further been reported that a daily dose of 3-4 gm of vancomycin will be required to provide 90% probability of attaining the target AUC/MIC of 400 for an isolate with MIC 1mg/L [18] .
While vancomycin has traditionally been considered a bactericidal agent, its potency is reduced to bacteriostatic levels in the setting of high-inoculum infections, stationary growth phase, or in an anaerobic environment. Decreased bactericidal activity (vancomycin tolerance) has been associated with higher vancomycin MIC. However, not all MRSA strains with a vancomycin MIC of 2mg/L are vancomycin tolerant. Vancomycin tolerance has been seen in 15% of wild-type MRSA strains compared with 74% of hVISA strains and 100% of VISA and VRSA strains [19] . This decreased bactericidal activity of vancomycin has been shown to be associated with poor clinical outcomes in bacteremia and can be independent of the MIC values [20] . Receipt of any vancomycin within 30 days predicts bacteriostatic activity among MRSA bacteremia isolates, whereas vancomycin-naïve patients with MRSA bacteremia can be expected to have isolates against which vancomycin is bactericidal [21] .
Phenotypic changes associated with decreased vancomycin susceptibility VISA has altered cellular physiology as a result of cumulative effects of mutations and/or modulation of regulatory systems. This altered physiology appears to change cell-wall metabolism in such a way as to result in increased numbers of D-Ala-D-Ala residues, which serve as dead-end binding sites for vancomycin. In addition, evaluation of S. aureus with reduced vancomycin susceptibility and isogenic vancomycin-susceptible progenitors showed cell walls with reduced peptidoglycan cross-linking, reduced cell-wall turnover, and reduced autolysis, causing considerable morphological cell-wall thickening. This altered cell wall results in a reduced diffusion coefficient of vancomycin, sequestration of vancomycin within the cell wall by these false targets, and prevention of vancomycin reaching its site of action [22] [23] [24] .
Vancomycin 'MIC creep' and clinical significance
Within the populations of S. aureus that are considered to be susceptible, a changing pattern of vancomycin MICs has been observed in some centers, demonstrating an overall population drift in the clinical isolates of S. aureus towards reduced vancomycin susceptibility. This phenomenon of "vancomycin MIC creep" varies considerably around the world and is summarized in Table 2 . However, it is important to point out that this is not universal and some centers have noted no changes or even reductions in vancomycin MIC creep (GS, unpublished observations). Thus, when large numbers of S. aureus samples are pooled together and analyzed from multiple centers, as in the SENTRY database study, center to center heterogeneity leads to a net neutralization effect, with no overall changes and clinical factors between study sites, including selective pressure generated by high-dose versus traditional use and dosing of vancomycin, severity of illness in the patient populations with different co-morbid conditions, difference in medical and surgical therapy of invasive S. aureus infections, and variation in susceptibility testing methods [25] . This variation is further confounded by the emergence of community-acquired MRSA and its prevalence in hospital settings. Community-acquired MRSA historically has a lower vancomycin MIC than MRSA from hospitals, presumably because of reduced vancomycin exposure, although virulence selection pressure may also play a role (discussed later). Furthermore, one needs to take reporting bias into account, whereby a Infections caused by S. aureus isolates with higher vancomycin MIC, even those in the susceptible range, have shown to be associated with various poor clinical outcomes, including delayed early response, increased mortality, increased rate of relapse, prolonged hospital stay or overall increased cost of hospitalization (see Table 3 ).
Vancomycin MIC creep has been observed in both methicillin-susceptible and -resistant S. aureus isolates [26, 27] . Interestingly, elevated vancomycin S. aureus MIC has been associated with increased mortality in patients with methicillin-susceptible S.aureus infections when they are treated with either vancomycin or flucloxacillin [27] .
Predictors for vancomycin resistance
Recent guidelines have suggested considering alternative antibiotics in complicated MRSA infection when vancomycin MIC is ≥2 μg/mL [28] . Various studies have attempted to identify patients at risk of infections with S. aureus with higher vancomycin MIC. This is important, as many hospitals estimate vancomycin MIC using automated methods and do not routinely provide a measured MIC value for the medical record. Also up to 90% of MRSA isolates with a MIC of 2μg/mL can be missed by some automated systems [11] . Infections caused by MRSA with higher vancomycin MIC are seen in patients with recent exposure to vancomycin within one month of the current infection, prior recent hospitalization, surgery within last 6 months and those with blood stream infections prior to admission in intensive care units [29] [30] [31] [32] . One recent study attempted to produce a score for high vancomycin MIC in MRSA blood stream infections using factors like age, prior vancomycin exposure, history of MRSA bacteremia, chronic liver disease, and presence of non-tunneled central venous catheter as predictors. Using these factors and the local rate of high vancomycin MIC, different cut-off points can be established and effectivly used to rule in or rule out an infection with an MRSA isolate with high vancomycin MIC and therefore help in selecting the early and empiric effective anti-MRSA therapy [33] .
Vancomycin "cross-resistance creeps"
Due to the complex nature of the mechanism of vancomycin heteroresistance, which represents a summation of a combination of genetic and gene expression events, it would be expected that the vancomycin MIC creep would influence not only susceptibility to vancomycin but other antibiotics as well. This hypothesis has been validated extensively in the literature with daptomycin, a cyclic lipopeptide of a different antibiotic class and mechanism of action. S. aureus strains with higher vancomycin MICs also tend to have higher daptomycin MICs [34] . As one "climbs the ladder" of vancomycin resistance, increasing daptomycin nonsusceptibility is observed, with about 50% of VISA being daptomycin nonsusceptible [35] . This selection of daptomycin nonsusceptibility by vancomycin occurs without exposure to daptomycin [36] . While the molecular mechanism(s) remain unknown, this cross-heteroresistance between vancomycin and daptomycin has important clinical implications. First, it further underscores the danger of vancomycin underdosing, as selection of hVISA and VISA in an infection like endocarditis, which contains a large number of organisms. Secondly, given the less likely scenario of daptomycin selecting for vancomycin heteroresistance, debates have surfaced towards using daptomycin rather than vancomycin as first line therapy, particularly in healthcare settings where vancomycin MICs of 2 mg/L are expected. While microbiologically sound, daptomycin is much more costly, and consequently physicians may be reluctant to use it during the first 24-72 hour window where blood cultures are pending. Third, use of daptomycin in salvage of vancomycin failure in MRSA bacteremia has been suggested at higher than approved doses of 8 mg/kg/day rather than the approved 6 mg/kg/day dose [28] . While unproven in benefit, higher doses are recommended when prior vancomycin has already reduced the potency of daptomycin, both in terms of increasing MIC and tolerance. Nevertheless, case reports demonstrate that the prior selection of daptomycin heteroresistance by vancomycin is not universally overcome with high-dose daptomycin monotherapy, and combination therapy with aminoglycosides is recommended. We have reported great success using daptomycin in combination with antistaphylococcal beta-lactams in the most recalcitrant cases of MRSA bacteremia [37] .
Vancomycin heteroresistance and implications for virulence
Knowledge of the innate host response has revealed that it consists, in part, of antimicrobial peptides produced by various cell types (e.g. cathelicidins, defensins, platelet microbicidal proteins) that serve to kill invasive pathogens. These antimicrobial peptides can be viewed in simple terms as endogenous antibiotic molecules produced by mammals. Thus, it would be conceivable that cross-resistance may occur between prokaryotic antibiotics and the antimicrobial peptides of mammals. While this area remains largely unexplored, evidence is emerging which demonstrates cross-resistance between platelet microbicidal proteins (cationic peptides produced by platelets) and vancomycin and daptomycin. Platelet microbicidal protein is believed to be an important innate host response mechanism that clears bacteria from the bloodstream when transient bacteremia occurs under physiologic circumstances. Thus, resistance to platelet microbicidal proteins has been shown to be an important virulence factor in the ability to establish an endovascular infection, like bacterial endocarditis.
In S. aureus, selection pressure by vancomycin in vivo and in vitro co-selects for platelet microbicidal protein resistance [38] . Thus, a vancomycin MIC creep seen in MRSA from patients previously treated with vancomycin carries with it consequences that extend beyond vancomycin susceptibility and pharmacodynamics. MRSA with higher vancomycin MIC may be less susceptible not only to daptomycin but also platelet microbicidal proteins and potentially other antimicrobial peptides of the innate host response. The downstream consequences of these phenotypes, including the risk of endocarditis in patients previously treated with vancomycin, requires further study.
It is an oversimplification, however, to say that S. aureus strains with higher vancomycin MICs are more virulent, as the virulence machinery of this pathogen is extremely elegant and complex. In fact, there is evidence toward the contrary when one considers traditional measures of virulence, such as severity of illness as well as laboratory in vivo models [39] . In one study, while higher vancomycin MICs were related to higher mortaility in MRSA bacteremia, vancomycin MIC was inversely related with symptoms of septic shock [40] . Other studies have shown that while hVISA is associated with prolonged bacteremia, it is inversely associated with mortality [41, 42] .
Conclusions
Using vancomycin as the cornerstone of MRSA therapy for the past five decades, particularly in the last 20 years, has exerted considerable selection pressure on S. aureus strains in the healthcare setting. While > 99% of clinical S. aureus isolates remain susceptible to vancomycin, the vancomycin MIC creep seen in many institutions demonstrates that this organism has not remained inert to this pressure. While appearing subtle by the relatively crude assays used in clinical microbiology laboratories, evidence is emerging suggesting that the vancomycin MIC creep is just the tip of the iceberg with regards to clinical consequences. Further complicating the matter is the variability in vancomycin MIC obtained between agar-based Etest and broth microdilutions, both automated and manual.
Physicians and pharmacists are meeting these challenges in a variety of ways, including: i) the adoption of rapid molecular tests to quickly differentiate MRSA from betalactam susceptible strains and, therefore, convert patients with the latter more rapidly to superior beta-lactam therapy; ii) optimization of vancomycin doses; iii) switching early to alternative agents when vancomycin MIC is 2 mg/L; iv) using combination antibiotic therapy; and v) abandoning vancomycin altogether in serious MRSA infections.
While all of these have theoretical benefits and, in some single center experiences, have actually shown benefit, the case for global generalizability of these countermeasures remains unproven.
Vancomycin has yet to be demonstrated to be inferior to any of the novel agents against MRSA bacteremia in prospective multi-center studies. This may reflect the fact that many clinical trials exclude the extremely difficult circumstances where enhanced activity in laboratory settings of novel agents may translate into a clinical benefit. Trials examining subgroups of patients representative of these most difficult cases would be extremely difficult to perform. Many questions remain unanswered and the bridge between laboratory science and clinical medicine is still in the early stages of development. What is clear is that S. aureus infections will remain a challenge for years to come for physicians, microbiologists, pharmacists, scientists, and, most importantly, patients. 
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